MOTS-c is described as a mitochondrial-derived peptide encoded within mitochondrial 12S rRNA. Research has examined its relationship to cellular metabolism, stress responses, and signaling in cell and animal models. The field is scientifically active, but most findings remain preclinical and do not establish a human treatment role.
What is MOTS-c?
Mitochondrial-derived peptides are short peptides reported from small open reading frames within mitochondrial transcripts. This classification differs from nuclear-encoded peptides that act on mitochondria. Sequence identity and analytical form should be documented explicitly because the name “MOTS-c” alone does not establish the contents of a commercial sample.
A reference database record can provide sequence and molecular information. A batch report must separately show how an analyzed sample relates to the product offered for research procurement.
Preclinical research context
Lee and colleagues reported cell and mouse studies involving metabolic homeostasis and diet-related phenotypes. Later research and reviews have examined exercise, aging, glucose handling, skeletal muscle, bone, and stress-response models. These studies differ in species, experimental design, route, endpoints, and molecular context.
Animal changes under controlled experimental conditions are not proof of weight loss, performance enhancement, or disease treatment in humans. LiveWire does not translate those endpoints into commercial benefit claims.
Translational evidence
Reviews discuss associations between endogenous MOTS-c, age, metabolic states, and human cohorts, as well as early translational hypotheses. Observational associations cannot determine causation, and measured endogenous peptide biology is not equivalent to administering an exogenous research material.
Clinical evidence remains limited relative to preclinical work. Questions about pharmacology, formulation, dose-response, safety, assay standardization, and long-term outcomes require controlled investigation. This overview offers no protocol or administration guidance.
Current regulatory context
FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting considered MOTS-c free base and acetate among nominated bulk substances. The meeting record states the uses FDA evaluated for the committee discussion. It does not itself constitute approval of MOTS-c as a drug product or authorize LiveWire’s research listing for human use.
Evidence limitations
- Much of the mechanistic evidence comes from cell and animal models.
- Endogenous associations do not establish effects of an external research material.
- Assays and sequence/form definitions can differ across studies.
- Current regulatory review is not equivalent to drug approval.
- Scientific literature does not certify a vendor batch.
Related LiveWire resources
Use the MOTS-c Research Database record for structured reference facts. The separate MOTS-c 40 mg product page supports RUO procurement and states batch-documentation status without making human-use claims.
Endogenous peptide versus research material
Studies measuring circulating or tissue-associated MOTS-c examine endogenous biology. Experiments adding synthetic peptide examine an intervention under defined conditions. These evidence streams can inform each other, but they are not interchangeable. Associations between endogenous levels and age or metabolic markers do not predict the effect of an externally supplied material.
Analytical assays for short circulating peptides can face specificity, sensitivity, matrix, and pre-analytical challenges. Researchers should examine how MOTS-c was measured and whether the assay distinguished related species.
Replication and model boundaries
The founding 2015 work generated important hypotheses, but a mature evidence map considers independent replication, sex and age of animals, diet, tissue, timing, and laboratory methods. Reviews can reveal areas with many mechanistic papers but little controlled human evidence.
The current FDA committee record adds regulatory context, not proof of efficacy. Research procurement should remain anchored to exact identity and batch documentation while scientific conclusions remain anchored to the model.
Add LiveWire as a preferred source
Use Google’s standard Preferred Sources control to make LiveWire Peptides easier to find in supported Google experiences.
References
- Bailly-Chouriberry L, Cormant F, Garcia P, et al.. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. The AAPS Journal. 2023. PMID 36949371 Peer-reviewed primary/methods literature
- U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Materials. 2026 Authoritative current regulatory record
- Lee C, Zeng J, Drew BG, Sallam T, et al.. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015. PMID 25738459 Peer-reviewed primary literature
- Zheng Y, Wei Z, Wang T. MOTS-c: A Promising Mitochondrial-Derived Peptide for Therapeutic Exploitation. Frontiers in Endocrinology. 2023. PMID 36761202 Peer-reviewed review